Latest News

Epilepsy community seeks redefinition of bioequivalence from FDA

For several years, epilepsy practitioners have questioned the U.S. Food and Drug Administration?s (FDA) definition of bioequivalence as it applies to narrow therapeutic index (NTI) drugs, such as those used for epilepsy. In response to these concerns, the FDA has sponsored 3 studies of antiepileptic drugs and also convened an advisory board to help determine which drugs are NTI.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Alzheimer's: The killer protein, properly explained

  • New study of freelance workers examines link between their well-being and hours worked

  • Classroom behaviour and dyslexia research

  • Specific neurotransmitter receptor supports optimal information processing in the brain

  • 'Exploding head syndrome' common in young people: Nearly 1 in 5 startled by loud, non-existent noises

  • New therapeutic target may improve treatment for brain cancer

  • New compounds could offer therapy for multitude of diseases

  • Stem cells make similar decisions to humans

  • Why good solutions make us oblivious to better ones

  • When attention is a deficit: Sometimes a new strategy makes sense

  •